User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

4322

Interactions with Platform & by Email *

INTERACTIONS

778

Unique # Participated *

PARTICIPANTS

130

Responses Validated *

VALIDATIONS

37

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Respiratory Diseases Common and Serious.....II-1
COPD A Debilitating Disease.....II-1
COPD Fact File: Prevalence.....II-1
1$100
   COPD Fact File: Mortality.....II-2
COPD Fact File: Smoking as the Leading Cause.....II-2
COPD - Economic Burden.....II-2
1$100
   Table 1: COPD Related Costs (Including Direct and Indirect Costs) Per Patient Aged Over 40 Years (includes corresponding Graph/Chart).....II-31$350
   Current & Future Analysis.....II-4
Market Overview.....II-4
Market Outlook.....II-4
1$100
   Maintenance Therapies to Continue Lead.....II-5
Treatment of Inflammation An Unmet Need.....II-5
1$100
   Competitive Landscape.....II-6
Table 2: World COPD Market by Major Drugs (2006): Value Sales for Advair, Spiriva, Combivent, Symbicort, and Atrovent (includes corresponding Graph/Chart).....II-6
1$350
   Table 3: World Leading Inhaled COPD/Asthma Drugs (2007): Value Sales for Advair, Symbicort, Pulmicort, Flovent, Asmanex, Serevent, Foradil, Spiriva, Atrovent, Combivent (includes corresponding Graph/Chart).....II-71$350
   The COPD Drug Discovery.....II-8
Bronchodilators Pipeline.....II-8
List of Potential Bronchodilator (LABA Inhaled) Candidates in Drug Development
  Pipeline.....II-8
List of Potential Bronchodilator (LAMA Inhaled) Candidates in Drug Development
  Pipeline.....II-8
1$100
   Anti-inflammatories Pipeline.....II-9
List of Potential Anti-inflammatory (Inhaled Corticosteroid) Candidates in Drug
  Development Pipeline.....II-9
List of Potential Anti-inflammation Agents (Anti- Leukotriene-oral) Candidates
  in Drug Development Pipeline.....II-9
List of Potential Anti-inflammation Agents (Phophodiesterase-4 Inhibitors-oral)
  Candidates in Drug Development Pipeline.....II-9
Combination Products Pipeline.....II-9
List of Potential Combination Products (LABA/ICS Combination-inhaled) in Drug
  Development Pipeline.....II-9
List of Potential Combination Products (LABA/LAMA) in Drug Development
  Pipeline.....II-9
1$100
   Pipeline Drugs with Novel Mode of Action.....II-10
List of Novel Approaches to COPD Treatment in Drug Development Pipeline.....II-10
1$100
   Chronic Obstructive Pulmonary Disease Synopsis.....II-11
The Normal Lung Functioning.....II-11
The Lung Functioning in COPD.....II-11
Risk Factors.....II-11
1$100
   Signs and Symptoms.....II-12
Diagnosis.....II-12
The Misconception.....II-12
Management Guidelines.....II-12
1$100
   GOLD Recommended Management of COPD: Stage 0.....II-13
GOLD Recommended Management of COPD: Stage II.....II-13
GOLD Recommended Management of COPD: Stage III.....II-13
GOLD Recommended Management of COPD: Stage IV.....II-13
1$100
   Treatment Options.....II-14
Therapeutic Options.....II-14
Bronchodilators.....II-14
1$100
   Beta2-agonists.....II-15
Short-acting Beta2-agonists.....II-15
1$100
   List of Prescription Short-acting Beta2-agonists.....II-16
Long-acting Beta2-agonists.....II-16
A Comparison of Leading Two LABAs : Salmeterol and Formoterol.....II-16
List of Prescription Long-acting Beta2-agonists.....II-16
1$100
   Anticholinergics.....II-17
Short-acting Anticholinergics.....II-17
List of Short-acting Prescription Anticholinergics.....II-17
Long-acting Anticholinergics.....II-17
1$100
   Methylxanthines.....II-18
List of Methylxanthines and Their Route of Administration.....II-18
Anti-inflammatories.....II-18
Inhaled Steroids.....II-18
1$100
   List of Inhaled Steroids and their Route of Administration.....II-19
Oral Steroids.....II-19
List of Tablet Steroids and their Route of Administration.....II-19
Combination Therapies.....II-19
1$100
   List of Prescription Combination Products.....II-201$100
   AEterna Zentaris Signs Agreement to Acquire All AEZS-130 Assets from Ardana.....II-21
Nycomed and Forest Sign Exclusive US Accord for Daxas.....II-21
Schering-Plough Revises Collaboration with Novartis.....II-21
1$100
   AstraZeneca Extends Research Collaboration with Dynavax.....II-22
GlaxoSmithKline and Mitsubishi Tanabe Sign Co-marketing Deal for Adoair.....II-22
1$100
   SeQual Technologies and AOTI Form Partnership.....II-23
Revotar Biopharma Secures Research Grant.....II-23
Argenta Discovery Announces Milestone Achievement.....II-23
Vectura Receives Milestone Payment.....II-23
Vectura Inaugurates New Laboratory Facility.....II-23
1$100
   MicroDose Technologies Announces Name Change to MicroDose Therapeutx.....II-24
Boehringer Ingelheim to Take Over Actimis Pharmaceuticals.....II-24
Novartis to Acquire Pulmonary Unit of Nektar.....II-24
1$100
   Tongjitang Chinese Medicine Plans Pulante Pharma Acquisition.....II-25
Sepracor, Arrow Announce Global Agreement for Combination Inhalation Solution.....II-25
Nycomed Canada and Chiesi Farmaceutici form Licensing Agreement.....II-25
1$100
   Sepracor, Arrow Sign Technology License and Development Agreement.....II-26
Teva Specialty Pharmaceuticals Announces Respiratory Deal with UCB.....II-26
3M Drug Delivery and Cambridge Consultants Sign Exclusive Agreement.....II-26
1$100
   Sanofi-aventis Announces Collaboration with Johns Hopkins University.....II-27
Lupin Enters Long-Term Accord with Forest Laboratories.....II-27
Ingen Signs Agreements with Batterjee Medical and Progressive International.....II-27
AstraZeneca, Silence Therapeutics Enter into Collaboration.....II-27
Vectura Announces Sandoz as Partner for VR315 and VR632.....II-27
1$100
   Air Products Divests A&J Care and COPD Services.....II-28
Parion Sciences Receives Milestone Payment for Pulmonary Disease Drug.....II-28
Almirall Receives Payment from Forest Laboratories for Aclidinium Bromide.....II-28
AstraZeneca Announces EPO Ruling for Symbicort Patent.....II-28
1$100
   Inverness Medical Announces Alere Medical Acquisition.....II-29
Respironics Takes Over J.H. Emerson.....II-29
Alkermes Enters into Joint Collaboration with Indevus Pharmaceuticals.....II-29
Aradigm Enters into Collaboration Agreement with CyDex.....II-29
1$100
   Critical Therapeutics and Dey Sign Co-Promotion Agreement.....II-301$100
   AstraZeneca Wins US Approval for Symbicort.....II-31
Novartis Secures EC Approval for New Oral COPD Drug, Onbrez Breezhaler.....II-31
Nycomed Submits MMA for New Oral Drug, Daxas, to the EMEA.....II-31
1$100
   Nycomed Files for Daxas Approval with the FDA.....II-32
Novartis Receives FDAs CRL for Investigational COPD Bronchodilator, QAB149.....II-32
3M Drug Delivery Launches Two New Dry Powder Inhalers.....II-32
GlaxoSmithKline Announces FDA Approval of Advair Diskus 250/50.....II-32
1$100
   Deys Perforomist Inhalation Solution Wins FDA Approval for COPD.....II-33
Boehringer, Pfizer Win EU Approval for Spiriva Respimat.....II-33
1$100
   AstraZeneca Plc (UK).....II-34
Boehringer Ingelheim GmbH (Germany).....II-34
GlaxoSmithKline PLC (UK).....II-34
1$100
   Novartis AG (Switzerland).....II-351$100
   Nycomed S.C.A. SICAR (Switzerland).....II-36
Schering-Plough Corporation (US).....II-36
1$100
   Sepracor, Inc. (US).....II-37
Vectura Group plc (UK).....II-37
1$100
   Table 4: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-381$350
   Table 5: World 10-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-391$350
   A. Market Analysis.....III-1
Current & Future Analysis.....III-1
COPD Prevalence.....III-1
Table 6: COPD Prevalence Data in American Adults Aged 18 Years and Over in the US (includes corresponding Graph/Chart).....III-1
1$200
   Chronic Bronchitis Data.....III-2
Table 7: Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients by Gender: 2007 (includes corresponding Graph/Chart).....III-2

Table 8: Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients by Age Group: 2007 (includes corresponding Graph/Chart).....III-2
1$200
   Table 9: Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients by Ethnicity: 2007 (includes corresponding Graph/Chart).....III-3
Emphysema Data.....III-3
Table 10: Emphysema - Breakdown of Chronic Bronchitis Patients by Gender: 2007 (includes corresponding Graph/Chart).....III-3
1$200
   Table 11: Emphysema - Breakdown of Chronic Bronchitis Patients by Age Group: 2007 (includes corresponding Graph/Chart).....III-4

Table 12: Emphysema - Breakdown of Chronic Bronchitis Patients by Ethnicity: 2007 (includes corresponding Graph/Chart).....III-4
1$200
   Market Overview.....III-5
Table 13: US COPD Market by Major Drugs (2006): Value Sales for Advair, Spiriva, Combivent, Flovent, Atrovent, and Serevent (includes corresponding Graph/Chart).....III-5
1$200
   Table 14: US COPD Market by Major Drugs (2006): Total Prescriptions for Advair, Spiriva, Combivent, Flovent, Atrovent, and Serevent (includes corresponding Graph/Chart).....III-6

Table 15: US COPD/Asthma Market by Drug Class (2007 and 2008): Value Sales for Inhaled Steroids/ Combinations, Inhaled Beta Agonists, Leukotrines, and Inhaled Anticholinergics/ NSAIDs (includes corresponding Graph/Chart).....III-6
1$200
   Table 16: US COPD/Asthma Market by Drug Class (2007 and 2008): Total Prescriptions for Inhaled Steroids/ Combinations, Inhaled Beta Agonists, Leukotrines, and Inhaled Anticholinergics/ NSAIDs (includes corresponding Graph/Chart).....III-71$200
   Table 17: US COPD/Asthma Market by Leading Drugs (2007 and 2008): Value Sales for Advair/Diskus, Singulair, Spiriva, Symbicort, Pulmicort, and Flovent (includes corresponding Graph/Chart).....III-81$200
   Table 18: US COPD/Asthma Market by Leading Drugs (2007 and 2008): Total Number of Prescriptions for Advair/Diskus, Singulair, Spiriva, Symbicort, Pulmicort, and Flovent (includes corresponding Graph/Chart).....III-9
Patient Non-compliance Hinders Market Growth.....III-9
1$200
   Lack of Awareness A Major Bottleneck for Market Growth.....III-10
HFA-propelled Inhalers End the CFC-propelled Inhalers Era.....III-10
Strategic Corporate Developments.....III-10
5$175
   Product Approvals/Launches.....III-151$75
   Select Players.....III-162$100
   B. Market Analytics.....III-18
Table 19: US Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease - Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-18
1$200
   A. Market Analysis.....III-19
Current & Future Analysis.....III-19
China.....III-19
Market Overview.....III-19
Strategic Corporate Developments.....III-19
5$175
   Product Approvals.....III-241$75
   Select Players.....III-253$125
   B. Market Analytics.....III-28
Table 20: Rest of World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease - Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-28
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com